Aitia, the leader in the development and application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced a collaboration with Servier to create  new Gemini Digital Twins to help in the fight against Pancreatic Cancer.

Aitia, the leader in the application of causal AI and “Digital Twins” to discover and develop new drugs, announced today that data from its Multiple Myeloma Digital Twin model will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease.

G3 Therapeutics, a life sciences company that leverages large-scale multi-omic biological big data to develop life-changing therapeutics and diagnostics, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced results of research that identified new causes of ASCAD.

GNS, the leader in the application of causal AI and “Digital Twins” to discover and develop new drugs, announced today its rebranding as Aitia (pronounced “ay-tee-ah”). Aitia, derived from the Greek word for causality, will focus on further leveraging its Gemini Digital Twins to discover the next generation of breakthrough drugs to improve outcomes for patients…

GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced two abstracts and two oral poster presentations highlighting insight from the Gemini Digital Twin models in Alzheimer’s Disease and Multiple Myeloma will be included at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans…

GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as the new GNS Chair of the Board…

GNS and Servier, today announced a collaboration to advance drug discovery, translational, and clinical development efforts in Multiple Myeloma (MM).

GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor. 

3-year partnership will leverage biomarker database and AI for innovation to create“Digital Twins” that help uncover the complex biology driving Alzheimer’s Disease